Lynparza™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Ovarian cancer,LYNPARZA is indicated as monotherapy for the:, maintenance treatment of adult patients with advanced breast cancer susceptibility gene (BRCA) mutated (germline or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy. BRCA mutation status should be determined by an experienced laboratory using a validated test method., maintenance treatment of adult patients with platinum-sensitive relapsed high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. Prior treatment must have included at least 2 courses of platinum-based regimens.,Lynparza in combination with bevacizumab is indicated for the:, maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation (germline or somatic), and/or; genomic instability,HRD status should be determined by an experienced laboratory using a validated test method.Ovarian cancer,LYNPARZA is indicated as monotherapy for the:, maintenance treatment of adult patients who have advanced, high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer with a deleterious or suspected deleterious, breast cancer susceptibility gene (BRCA) mutation (germline or somatic), which is in response (complete or partial) to first-line platinum-based chemotherapy., maintenance treatment of adult patients who have platinum-sensitive relapsed, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer which is in response (complete or partial) after platinum-based chemotherapy. Prior treatment must have included at least 2 courses of platinum-based regimens.,LYNPARZA in combination with bevacizumab is indicated for the:, maintenance treatment of adult patients who have advanced, epithelial ovarian, fallopian tube or primary peritoneal cancer which is in response (complete or partial) to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:,- a deleterious or suspected deleterious BRCA mutation (germline or somatic), and/or,- genomic instabilityAdenocarcinoma of the pancreas,Lynparza is indicated as monotherapy for the:, maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Germline BRCA mutation (gBRCAm) status should be determined by an experienced laboratory using a validated test method.Prostate cancer,LYNPARZA is indicated as monotherapy for the:, treatment of adult patients with BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer who have progressed following prior therapy that included a new hormonal agent. BRCA mutation status should be determined by an experienced laboratory using a validated test method.Breast cancer,LYNPARZA is indicated as monotherapy for the:, adjuvant treatment of adult patients who have HER2-negative, high-risk early breast cancer with a deleterious or suspected deleterious germline BRCA mutation (gBRCAm), for which they have previously been treated with neoadjuvant or adjuvant chemotherapy., treatment of adult patients who have HER2-negative metastatic breast cancer with a deleterious or suspected deleterious gBRCAm, for which they have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.Prostate cancer,LYNPARZA is indicated as monotherapy for the:, treatment of adult patients who have metastatic castration-resistant prostate cancer (mCRPC) with a deleterious or suspected deleterious BRCA mutation (germline or somatic), which has progressed following prior therapy that included a new hormonal agent.,LYNPARZA in combination with abiraterone and either prednisone or prednisolone is indicated for the:, treatment of adult patients who have mCRPC with a deleterious or suspected deleterious BRCA mutation (germline or somatic).Adenocarcinoma of the pancreas,LYNPARZA is indicated as monotherapy for the:, maintenance treatment of adult patients who have metastatic pancreatic adenocarcinoma with a deleterious or suspected deleterious gBRCAm, which has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Source: ARTG

• Shelf lifetime is 4 Years
• Store below 30 degrees Celsius
• Protect from Moisture; Store in Original Container

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Tablet, film coated
• Oral
• Yellow to dark yellow film-coated, oval, biconvex tablet, debossed with 'OP 100' on one side and plain on the reverse

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 56 tablets

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:

• 12932P (Opens in new tab)
• 12170M (Opens in new tab)
• 13782J (Opens in new tab)
• 13783K (Opens in new tab)
• 11503K (Opens in new tab)
• 11522K (Opens in new tab)
• 12921C (Opens in new tab)
• 12169L (Opens in new tab)
• 14181J (Opens in new tab)
• 14216F (Opens in new tab)
• 14689D (Opens in new tab)

Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Olaparib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).